7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $213M | -$59M | 79.8% | -25.5% | -$29M | $57M | $11M |
| 2024 | $209M | -$56M | 80.4% | -26.6% | -$49M | $53M | $11M |
| 2023 | $187M | -$50M | 81.2% | -27.5% | -$46M | $53M | $13M |
| 2022 | $142M | -$43M | 82.0% | -24.6% | -$45M | $53M | $19M |
| 2021 | $94M | -$21M | 82.1% | -17.5% | -$20M | $29M | $106M |
| 2020 | $57M | -$4M | 78.3% | 1.5% | -$6M | $31M | $18M |
| 2019 | $39M | -$4M | 80.6% | -9.0% | -$9M | — | $12M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $47M | -$18M | 79.3% | -36.4% | $4M | $58M | $10M |
| Dec '25 | $63M | -$9M | 80.6% | -9.5% | -$10M | $57M | $11M |
| Sep '25 | $50M | -$16M | 79.1% | -31.2% | -$12M | $55M | $8M |
| Jun '25 | $47M | -$17M | 79.7% | -35.8% | -$8M | $55M | $8M |
| Mar '25 | $53M | -$16M | 79.7% | -29.6% | $655000 | $53M | $13M |
| Dec '24 | $69M | -$501000 | 80.7% | -0.3% | -$7M | $53M | $11M |
| Sep '24 | $45M | -$15M | 80.1% | -33.6% | -$15M | $53M | $12M |
| Jun '24 | $44M | -$21M | 80.2% | -48.1% | -$16M | $53M | $18M |
| Mar '24 | $51M | -$19M | 80.2% | -37.1% | -$11M | $53M | $9M |
| Dec '23 | $62M | -$6M | 81.6% | -10.9% | -$2M | $53M | $13M |
| Sep '23 | $41M | -$18M | 80.4% | -43.7% | -$13M | $53M | $7M |
| Jun '23 | $42M | -$12M | 81.7% | -31.1% | -$13M | $53M | $12M |
| Mar '23 | $42M | -$13M | 80.9% | -32.6% | -$19M | $53M | $30M |
| Dec '22 | $50M | -$4M | 81.9% | -7.0% | -$8M | $53M | $19M |
| Sep '22 | $33M | -$12M | 81.6% | -34.2% | -$13M | $53M | $89M |
| Jun '22 | $30M | -$17M | 82.3% | -39.8% | -$16M | $53M | $102M |
| Mar '22 | $29M | -$9M | 82.3% | -27.9% | -$9M | $29M | $98M |
| Dec '21 | $33M | -$7M | 81.1% | -16.7% | -$5M | $29M | $106M |
| Sep '21 | $22M | -$6M | 80.4% | -25.3% | -$10M | $29M | $109M |
| Jun '21 | $21M | -$5M | 80.9% | -19.6% | -$4M | $29M | $120M |
How the market has priced TMCI against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Treace Medical Concepts, Inc.'s revenue has grown 30.0% per year. These are computed facts, not advice.
As of FY2025, Treace Medical Concepts, Inc. reported $57M of total debt against $11M of cash; operating income covered interest expense -10.2×.
In FY2025, gross margin was 79.8%, operating margin -25.5%, and net margin -27.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.